Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Palandri

Showing results (81-90 of 187) with videos related to

Pageof 19
Sort By:
Cancer Medicine|April 10, 2026
Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial AnalysisRuben Mesa, Jeanne M Palmer, Francesca Palandri, et al.
The Oncologist|May 25, 2026
Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 studyJean-Jacques Kiladjian, Uma Borate, Elisabetta Abruzzese, et al.
Haematologica|March 28, 2008
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcomeFrancesca Palandri, Ilaria Iacobucci, Fausto Castagnetti, et al.
Drug Design, Development and Therapy|June 2, 2015
Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating studyNicola Cascavilla, Valerio De Stefano, Fabrizio Pane, et al.
Ejhaem|December 5, 2022
Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosisNaveen Pemmaraju, Claire Harrison, Vikas Gupta, et al.
Annals of Hematology|July 5, 2024
FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)Susanne Isfort, Nikolas von Bubnoff, Haifa Kathrin Al-Ali, et al.
Annals of Hematology|December 14, 2019
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practiceMassimo Breccia, Claudia Baratè, Giulia Benevolo, et al.
Journal of Cancer Research and Clinical Oncology|March 8, 2023
Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in GermanyAndreas Schmidt, Christiane Bernhardt, Dieter Bürkle, et al.
Blood Neoplasia|June 2, 2025
Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal responseNaveen Pemmaraju, Tim C P Somervaille, Francesca Palandri, et al.
Annals of Hematology|June 16, 2019
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosisMassimo Breccia, Luigiana Luciano, Novella Pugliese, et al.
Pageof 19

Showing results (81-90 of 187) with videos related to

Sort By:
Pageof 19
Cancer Medicine|April 10, 2026
Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial AnalysisRuben Mesa, Jeanne M Palmer, Francesca Palandri, et al.
The Oncologist|May 25, 2026
Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 studyJean-Jacques Kiladjian, Uma Borate, Elisabetta Abruzzese, et al.
Haematologica|March 28, 2008
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcomeFrancesca Palandri, Ilaria Iacobucci, Fausto Castagnetti, et al.
Drug Design, Development and Therapy|June 2, 2015
Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating studyNicola Cascavilla, Valerio De Stefano, Fabrizio Pane, et al.
Ejhaem|December 5, 2022
Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosisNaveen Pemmaraju, Claire Harrison, Vikas Gupta, et al.
Annals of Hematology|July 5, 2024
FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)Susanne Isfort, Nikolas von Bubnoff, Haifa Kathrin Al-Ali, et al.
Annals of Hematology|December 14, 2019
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practiceMassimo Breccia, Claudia Baratè, Giulia Benevolo, et al.
Journal of Cancer Research and Clinical Oncology|March 8, 2023
Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in GermanyAndreas Schmidt, Christiane Bernhardt, Dieter Bürkle, et al.
Blood Neoplasia|June 2, 2025
Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal responseNaveen Pemmaraju, Tim C P Somervaille, Francesca Palandri, et al.
Annals of Hematology|June 16, 2019
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosisMassimo Breccia, Luigiana Luciano, Novella Pugliese, et al.
Pageof 19